Heated Intraperitoneal Chemotherapy (HIPEC) for Mesothelioma
A patient and family guide to heated chemotherapy during surgery for peritoneal mesothelioma.
What Is Heated Intraperitoneal Chemotherapy (HIPEC)?
Heated intraperitoneal chemotherapy (HIPEC) is a treatment that circulates warmed anticancer medicine inside the abdominal cavity during an operation. For selected people with peritoneal mesothelioma—cancer affecting the lining of the abdomen—it is commonly considered together with cytoreductive surgery (CRS), which aims to remove visible tumor. HIPEC is not an operation by itself and is not the same as chemotherapy delivered through an IV.
The goal is to expose microscopic cancer cells remaining in the abdomen to chemotherapy after the surgeon has removed as much visible disease as safely possible. Neither CRS nor HIPEC guarantees a cure, and not every patient is a candidate. A specialist team should explain the expected benefit, the uncertainty in the evidence, and the risks for your situation.
| Term | Plain-language meaning |
|---|---|
| Peritoneal mesothelioma | Mesothelioma arising in the abdominal lining |
| CRS | Operation to remove visible tumor deposits |
| HIPEC | Heated chemotherapy circulated within the abdomen during surgery |
| Systemic chemotherapy | Cancer medicines given through the bloodstream |
For an overview of operations, see surgery for mesothelioma.
How HIPEC Works With Cytoreductive Surgery
CRS comes first. The surgeon inspects the abdomen and removes tumor deposits where removal is feasible, sometimes including affected portions of the peritoneum or other tissue. The team then circulates a heated chemotherapy solution through the abdominal cavity for a protocol-specific period, drains it, and completes the operation. Exact drugs, temperature, timing and surgical techniques vary by center and patient; there is no safe do-it-yourself or universal protocol.
The National Cancer Institute describes HIPEC as a regional approach used after visible cancer has been removed. Because the medicine contacts abdominal surfaces directly, it has a different delivery method from IV chemotherapy, but it can still produce whole-body side effects.
| Treatment component | Purpose | Important limitation |
|---|---|---|
| CRS | Remove visible abdominal disease | May not be possible to remove all disease safely |
| HIPEC | Treat remaining microscopic cells on abdominal surfaces | Cannot ensure every cancer cell is eliminated |
| IV chemotherapy | Treat cancer through the bloodstream | May be used before or after surgery or instead of surgery |
Read more about cytoreductive surgery for mesothelioma.
Who May Be Eligible for CRS and HIPEC?
Eligibility depends on tumor distribution, mesothelioma cell type, imaging, fitness for a major operation, kidney function, nutritional status, other medical conditions, and whether a surgeon expects that visible disease can be substantially removed. Age alone does not settle the decision; the team evaluates overall health and personal goals. Disease outside the abdomen or extensive tumor involvement may make the procedure inappropriate.
Ask for review by a multidisciplinary team at a center experienced in peritoneal surface malignancies. A 2024 multisociety consensus supported CRS-HIPEC for carefully selected patients while describing the underlying evidence as very low certainty. An earlier 2020 guideline called for specialist-center assessment and research protocols rather than treating it as universally established. These recommendations differ in strength, underscoring the need for individualized discussion.
| Assessment | Why the team checks it |
|---|---|
| CT or other imaging | Estimate location and extent of disease |
| Pathology review | Confirm diagnosis and histologic subtype |
| Heart, lung and kidney evaluation | Assess operative and chemotherapy safety |
| Performance and nutrition | Estimate ability to tolerate and recover |
| Surgical review | Determine likelihood of adequate tumor removal |
A second opinion can help when eligibility or treatment goals are unclear.
Preparing for CRS and HIPEC
Preparation typically includes a detailed surgical consultation, medication reconciliation, blood tests, anesthesia evaluation, nutrition assessment and a plan for recovery support. Tell the team about blood thinners, supplements, allergies, kidney problems, prior abdominal operations and any recent fever or infection. Never stop prescribed medicines unless your clinicians tell you to.
Because the operation can be extensive, arrange transportation, help at home, time away from work and a reliable contact person. Ask which costs are covered by insurance, whether prior authorization is required, and what lodging may be needed if you travel to a specialty center.
| Before surgery | Question or action |
|---|---|
| Medication review | Which medicines or supplements should I change, and when? |
| Nutrition | Should I meet a dietitian or address weight loss? |
| Home support | Who can assist with meals, mobility and appointments? |
| Coverage | Are the surgeon, hospital and postoperative services in network? |
For logistics, see managing travel and lodging during treatment.
What Happens on Treatment Day?
The surgical and anesthesia teams confirm the plan, provide general anesthesia and perform the cytoreductive operation. If the findings and patient condition permit, the team then delivers HIPEC through specialized equipment. The treatment solution is removed before the operation is completed. The length of the procedure depends heavily on how extensive the surgery is; your team should provide its own estimate rather than relying on a generic number.
Some patients need intensive monitoring immediately afterward, while others recover in a surgical unit. Tubes, drains, IV fluids and pain medication may be needed. If the surgeon discovers that safe, meaningful cytoreduction is not possible, the team may change the operative plan or decide against HIPEC. Discuss this possibility and your preferences beforehand.
| Stage | What the patient can expect |
|---|---|
| Before anesthesia | Consent review and safety checks |
| Cytoreduction | Removal of visible tumor when feasible |
| HIPEC phase | Heated chemotherapy circulated within the abdomen |
| Immediate recovery | Monitoring of breathing, blood pressure, fluids and pain |
A caregiver can ask the hospital how and when operative updates will be shared.
Risks and Side Effects of HIPEC
CRS-HIPEC is major treatment with potentially serious complications. Surgical risks include bleeding, infection, blood clots, bowel injury or leaks, and prolonged recovery. Chemotherapy-related concerns can include kidney injury, changes in blood counts and nausea; the specific risk depends on the drug and dose used. The team should explain what it does to protect kidney function and monitor fluids and laboratory values.
An NCI professional summary reports substantial complications in historical observational cohorts, but those results come from selected patients and older treatment periods; they cannot predict an individual outcome. Discuss the center’s own current complication and mortality rates, the proposed operation, and alternatives.
| Possible problem | What to discuss |
|---|---|
| Fever or wound changes | When to call immediately about infection |
| Severe or increasing abdominal pain | Whether urgent evaluation is needed |
| Reduced urine output | Kidney function and dehydration concerns |
| Shortness of breath or chest pain | Emergency evaluation for possible serious complications |
| Persistent vomiting or inability to drink | Assessment for dehydration or bowel complications |
Seek emergency care for severe breathing difficulty, chest pain, fainting or other immediately dangerous symptoms. Follow your discharge instructions for fever, worsening pain, reduced urine output and inability to keep fluids down.
Recovery, Nutrition and Follow-Up
Recovery may take weeks to months, depending on the extent of surgery, complications and baseline health. The team will help manage pain, monitor bowel function, support gradual walking, and plan nutrition and hydration. Avoid lifting, driving or restarting strenuous activity until your surgeon gives individualized instructions. Patients with weight loss or difficulty eating may benefit from oncology dietitian support.
After discharge, follow-up visits may include wound checks, blood work, scans and discussion of additional treatment. Keep a list of symptoms, medicines, temperature readings when advised, and questions. New or worsening symptoms deserve evaluation rather than being assumed to be normal recovery.
| Recovery area | Practical plan |
|---|---|
| Activity | Follow the surgical team’s walking and lifting instructions |
| Food and fluids | Use the dietitian’s plan; report poor intake |
| Medication | Use only the prescribed pain and nausea regimen |
| Appointments | Schedule labs, scans and surgical follow-up |
| Caregiver support | Arrange help with transport, meals and household tasks |
Related guidance: recovery after mesothelioma treatment and hydration and electrolytes.
Potential Benefits, Evidence Limits and Questions to Ask
Specialist teams may offer CRS-HIPEC to carefully selected patients because observational studies have reported prolonged survival in some groups. However, selection bias is important: people healthy enough for extensive surgery and with disease that can be removed may already differ from people receiving other treatments. The best approach for an individual depends on disease characteristics, operative risk and goals.
The NCI notes that much of the evidence comes from retrospective studies. A 2024 multisociety consensus endorsed the approach for a selected subgroup but rated certainty of evidence very low; an earlier evidence-based guideline was more cautious. Ask your team how it interprets these differences and whether clinical trials or systemic treatment are appropriate.
| Ask the specialist | Why it matters |
|---|---|
| Can you remove most visible disease? | Expected completeness of surgery affects treatment planning |
| Which HIPEC drugs will you use? | Protocols and toxicities vary |
| What are your center’s complication rates? | Local experience informs risk discussion |
| What if HIPEC cannot be completed? | Clarifies the backup plan |
| What alternatives and trials exist? | Supports an informed choice |
Compare options in the surgery, chemotherapy and radiation comparison.
Frequently Asked Questions
Is HIPEC the same as ordinary chemotherapy?
No. HIPEC delivers heated chemotherapy into the abdominal cavity during surgery. Ordinary systemic chemotherapy circulates through the bloodstream; some patients may receive both at different times.
Is HIPEC used for pleural mesothelioma?
This page describes HIPEC for peritoneal mesothelioma. Treatment inside the chest uses different procedures and terminology; ask a pleural mesothelioma specialist about appropriate options.
Does HIPEC cure mesothelioma?
No cure can be promised. The aim is to remove visible disease and treat cells that may remain, but recurrence is possible.
Can every patient with peritoneal mesothelioma receive HIPEC?
No. Tumor distribution, overall health, organ function and whether meaningful tumor removal is feasible all influence eligibility.
Is HIPEC performed before or after cytoreductive surgery?
It is generally performed during the same operation after surgeons have removed as much visible tumor as safely possible.
What side effects should families watch for?
Follow the center’s instructions for fever, worsening abdominal pain, wound problems, poor fluid intake and reduced urine output. Seek emergency care for severe breathing difficulty, chest pain or fainting.
How long does recovery take?
Recovery varies with the extent of surgery and complications and can take weeks to months. The treating surgeon can give a more useful individualized estimate.
Should I seek a second opinion?
A consultation at a center experienced in peritoneal mesothelioma and CRS-HIPEC can clarify eligibility, risks, alternatives and available clinical trials.
Medical Sources and Further Reading
- National Cancer Institute: Mesothelioma Treatment — patient treatment overview.
- National Cancer Institute: Mesothelioma Treatment (Health Professional PDQ) — evidence and limitations for peritoneal disease.
- 2024 multisocietal consensus on CRS-HIPEC — recommendations for carefully selected patients and evidence certainty.
- 2020 clinical practice guideline — a more cautious evidence assessment and specialist-center referral.
Medical literature and recommendations evolve. Ask your specialist which guidance applies to your case.
Get Help With Mesothelioma Questions
Call 800.291.0963. Live chat available 24/7, 365 days a year. Submit Your Case to learn about available assistance. No legal or financial outcome is guaranteed.
⚕️ Legal & Medical Information Disclaimer
This page provides general education, not individualized medical or legal advice. Consult your oncology team about treatment and a qualified attorney about legal questions.